# Patent Watch: NUS Targets Cannabinoid Production With

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/patent-watch-patent-watch-nus-targets-cannabinoid-producti-2026-10-09/
> **Published:** 2026-10-09T12:15:05-04:00 | **Last Modified / Clinically Audited:** 2026-10-09T12:15:05-04:00
> **Clinical Summary:** The application concerns recombinant Saccharomyces cerevisiae cells designed for cannabinoid production, positioning yeast as a biological manufacturing pl

---

PATENT WATCH
 US20260258460A1
 
 

# Patent Watch: NUS Targets Cannabinoid Production With Engineered Yeast

 
 **Assignee:** National University of Singapore
 **Inventors:** Kevin Jie Han Lim, Maybelle Darlene Kho Go, Wen Shan Yew
 **Published:** 2026-09-03
 
 

 
 Invention Summary & Claims
 

The application concerns recombinant Saccharomyces cerevisiae cells designed for cannabinoid production, positioning yeast as a biological manufacturing platform rather than a patient-facing delivery system. The available disclosure does not identify specific cannabinoid outputs, genetic modifications, production yields, finished formulations, or pharmaceutical excipients.

 

 

## Clinical Perspective & Therapeutic Significance

 

If successfully developed, yeast-based production could support more consistent supplies of cannabinoid active pharmaceutical ingredients, including compounds that are difficult to obtain economically from plants. Clinical usefulness would still depend on ingredient purity, impurity control, formulation, dosing, and indication-specific evidence, with no demonstrated improvement in bioavailability or patient outcomes established here.

 

## Intellectual Property & Market Landscape

 

National University of Singapore is the listed applicant, placing this application within academic biotechnology rather than a disclosed finished cannabis product portfolio. Unlike conventional cannabis products derived from cultivated plants, this approach centers on microbial manufacturing, although its competitiveness against extraction and other biosynthetic platforms cannot be judged without yield, cost, and claim-scope data.

 
 **Official Source Document:** Review the primary patent disclosure and full claims on [Google Patents (US20260258460A1)](https://patents.google.com/patent/US20260258460A1/en).
 

 
 Editorial Commentary
 

The potential significance lies in cannabinoid manufacturing, not a demonstrated new treatment. Clinical adoption would require validated production quality and evidence supporting the resulting product for its intended use.

 

 
 

### Frequently Asked Questions

 
 Are cannabinoids made by engineered yeast different from plant-derived cannabinoids?
 A purified cannabinoid can have the same chemical identity regardless of its production source. [Product quality](https://cedclinic.com/cbd-gummies-guide-online-safe-guide-health-conscious-adults/), impurities, formulation, and dose still matter, and this application does not establish clinical equivalence for any finished product.

 Does this patent application prove that yeast-produced cannabinoids are safe or effective?
 No. A published patent application describes intellectual property claims, not regulatory approval or proof of clinical efficacy, and the available disclosure identifies no clinical trial results.

 When could patients access products made using this technology?
 No availability date is established by this application. Access would depend on successful scale-up, quality validation, commercialization, and applicable regulatory requirements.

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Cannabis Consultation](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).